Antibiotic resistance

A strain of multidrug-resistant Escherichia coli is on the rise

Escherichia coli, or E. coli, is a member of a group of Gram-negative Enterobacteriaceae that predominantly reside in the human gut. Their treatment is becoming increasingly challenging: in the fight against antibiotics E. coli bacteria and other Enterobacteriaceae have developed enzymes, so-called extended-spectrum beta-lactamases (ESBL), which render antibiotics ineffective. 

"We need to pay particular attention to a subset of multidrug-resistant E. coli bacteria which we have found in our current study,” explains Prof Trinad Chakraborty, Director of the Institute for Medical Microbiology at the JLU in Gießen and Coordinator at the DZIF partner site Gießen-Marburg-Langen. This subset is currently spreading globally and has now also been found in Germany.

Multidrug-resistant E. coli bacteria
Multidrug-resistant E. coli bacteria
Giessen University/Press Office

Genome sequencing for monitoring antibiotic resistance

In the study, the scientists from Gießen investigated almost 1000 isolates of ESBL-producing bacteria from humans, animals, the environment and food. Their approach is in-line with the One Health approach which not only includes humans but also the respective environment in investigations. They specifically identified beta-lactamase genes and searched for a subset which had already increasing in other countries: a multidrug-resistant strain of E. coli, sequence type 131 (ST131). This strain is responsible for millions of infections worldwide, particularly for blood stream and bladder infections, and carries a relatively rare ESBL gene called blaCTX-M-27. The quest was successful: the researchers found E. coli ST131 CTX-M27 to be exclusively present in the human isolates and could confirm that its incidence had increased from 0 % in 2009 to 45 % in 2016.

“With this, this E. coli strain and its specific ESBL gene has become a competitor for an E. coli ST131 strain carrying a different ESBL gene, which has been the most prevalent in Germany up to now,” explains Dr Can Imirzalioglu, scientist at the Gießen University. More studies are required to investigate the causes and clinical implications of this shift. However, the results highlight the importance of modern methods such as genome sequencing for observing developments like this and for reacting rapidly in emergencies.


Source: Deutsches Zentrum für Infektionsforschung

25.10.2017

Read all latest stories

Related articles

A new approach

"Universal antibodies" disarm various pathogens

Scientists from the German Cancer Research Center (DKFZ) have been studying how the immune system succeeds in keeping pathogens in check. For the first time, the researchers have now discovered…

Medication development

Support from the other end of the world

Partners who could hardly be further apart – yet have a lot in common – have united to fight resistant pathogens. The International Consortium for Anti-Infective Research (iCAIR) was founded last…

Enigmatic enzyme

How bacteria recover from antibiotics exposure

Beta-lactam antibiotics, including penicillin, are one of the most widely used classes of antibiotics in the world. Though they’ve been in use since the 1940s, scientists still don’t fully…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH